Urinary cystatin B differentiates progressive versus stable IRIS Stage 1 chronic kidney disease in dogs.

ABSTRACT:

Background

Early identification of dogs with progressive vs stable chronic kidney disease (CKD) might afford opportunity for interventions that would slow progression. However, currently no surrogate biomarker reliably predicts CKD progression.

Hypothesis/objectives

Urinary cystatin B (uCysB), a novel kidney injury biomarker, predicts progressive disease in International Renal Interest Society (IRIS) CKD Stage 1.

Animals

Seventy-two dogs, including 20 dogs from 4 university centers with IRIS CKD Stage 1, with IDEXX symmetric dimethylarginine (SDMA) concentration up to 17 μg/dL and no systemic comorbidities, and 52 clinically healthy staff-owned dogs from a fifth university center.

Methods

A multicenter prospective longitudinal study was conducted between 2016 a

SUBMITTER: Segev G 

PROVIDER: S-EPMC10658556 | biostudies-literature | 2023 Nov-Dec

REPOSITORIES: biostudies-literature